Regulatory Update: FDA Steps Up Debarment and Disqualification Efforts

Posted 01 September 2009 | By

The US Food and Drug Administration (FDA) recently enhanced its procedures for debarment and disqualification of noncompliant investigators and others as another step toward protecting clinical trial participants and ensuring the safety and effectiveness of the medical products marketed in the US.


Regulatory Focus newsletters

All the biggest regulatory news and happenings.